Foghorn Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
The pipeline features advanced protein degrader programs in oncology, with key assets progressing toward IND-enabling studies and a major partnered SMARCA2 program in dose escalation. Financial strength was bolstered by a recent $50 million offering, supporting ongoing R&D and clinical milestones.
-
The discussion highlighted the scientific rationale for targeting chromatin regulatory complexes in cancer, detailed progress on SMARCA2 (in partnership with Lilly) and wholly owned CBP/EP300 programs, and outlined clinical and preclinical advances. Key updates and expansion decisions are expected later this year.
Fiscal Year 2025
-
The company is advancing a precision oncology pipeline focused on chromatin regulation, with its lead 909 program in partnership with Lilly targeting SMARCA2 in non-small cell lung cancer. Strong enrollment and promising preclinical data support a potential move to first-line settings and pipeline expansion in 2024.
-
A major partnership with Eli Lilly drives the SMARCA2 program, with a key dose expansion decision expected in H1 2026. Proprietary assets targeting chromatin regulators are advancing toward IND, and the company is well-funded into early 2028.
-
Chromatin regulation is a key focus, with selective targeting of SMARCA2 in cancers with SMARCA4 loss showing strong preclinical and early clinical promise. The pipeline includes advanced CBP and EP300 programs and a novel ARID1B degrader, all aiming for improved selectivity and tolerability.
-
The conference detailed significant progress in developing selective protein degraders for cancer, including robust ARID1B, CBP, and EP300 programs, with multiple candidates advancing toward IND-enabling studies in 2026. Selective degradation strategies offer efficacy and safety advantages, and industry feedback on ARID1B was highly positive.
-
The discussion highlighted advances in targeting the chromatin regulatory system, with a focus on selective inhibition and degradation of challenging proteins like SMARCA2, CBP, and EP300. Key clinical trials are underway, with important data and potential new targets expected over the next 12–18 months.
-
New preclinical and clinical data highlight FHD909's strong anti-tumor activity in SMARCA4-mutated cancers, especially NSCLC, with promising results in combination therapies. The pipeline includes selective CBP, EP300, and ARID1B degraders, and the company is well-funded with strategic partnerships driving future growth.
-
The company presented advances in chromatin-targeted cancer therapeutics, highlighting clinical progress for SMARCA2 and preclinical breakthroughs for CBP, EP300, and ARID1B. Key data readouts and IND filings are expected over the next 6–15 months.
Fiscal Year 2024
-
The discussion highlighted a robust pipeline focused on chromatin regulation, with FHD-286 and FHD-909 advancing in phase I trials targeting AML and SMARCA4-mutant cancers, respectively. Key efficacy and safety benchmarks were discussed, and new ARID1B-targeting efforts show promise for broader cancer applications.
-
The discussion highlighted a robust pipeline targeting chromatin regulatory proteins, with key programs in clinical development for AML and non-small cell lung cancer. Strategic collaborations, novel inhibitor and degrader modalities, and a focus on synthetic lethality underpin future growth.
-
The company is advancing a chromatin biology platform with a focus on oncology, highlighted by FHD-286 in AML and a strategic partnership with Lilly for SMARCA2/4 programs. Key pipeline assets are progressing toward clinical milestones, supported by a strong cash position into 2027.